Profit Guidance

• Revenue expected to be around $2.30 billion
• Net profit after tax expected to be $450 million to $470 million
• Continuous improvement and efficiency gains contributing to margin improvements

Fisher & Paykel Healthcare Corporation Limited announced that it has updated its revenue and earnings guidance for the financial year ending 31 March 2026. The company now expects full year operating revenue to be approximately $2.30 billion, and net profit after tax to be in the range of approximately $450 million to $470 million. This updated guidance does not incorporate any potential refund of US tariffs paid to date during the 2026 financial year. The company has continued to see good growth across its Hospital products, and while seasonal respiratory hospitalisations may impact the second half, the performance to date suggests progress in changing clinical practice. Continuous improvement activities and other efficiency gains are also contributing to improvements in the company's gross margin and operating margin. The company notes that the United States Supreme Court has invalidated tariffs imposed by the US administration, but there are still uncertainties regarding the implications. The company continues to view current and proposed tariff structures in the context of cost increases that will be mitigated over time by the company's longstanding continuous improvement activities, and does not currently believe these matters have any material impact on the company's long-term direction, strategy or sustainable profitable growth.

Full year operating revenue expected to be approximately $2.30 billion, and net profit after tax expected to be in the range of approximately $450 million to $470 million for the financial year ending 31 March 2026.